## Supplemental Table 1. Correlations among inflammation and coagulation biomarkers.

<table>
<thead>
<tr>
<th></th>
<th>HIV-infected women, prior to HAART initiation</th>
<th>HIV-infected women, after HAART initiation</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>IL-10</td>
<td>TNF-a</td>
</tr>
<tr>
<td>IL-6</td>
<td>r</td>
<td>0.18</td>
</tr>
<tr>
<td></td>
<td>P</td>
<td>0.047</td>
</tr>
<tr>
<td>IL-10</td>
<td>r</td>
<td>0.57</td>
</tr>
<tr>
<td></td>
<td>P</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>TNF-a</td>
<td>r</td>
<td>0.32</td>
</tr>
<tr>
<td></td>
<td>P</td>
<td>0.000</td>
</tr>
<tr>
<td>D-dimer</td>
<td>r</td>
<td>0.17</td>
</tr>
<tr>
<td></td>
<td>P</td>
<td>0.058</td>
</tr>
<tr>
<td>MCP-1</td>
<td>r</td>
<td>0.34</td>
</tr>
<tr>
<td></td>
<td>P</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>sCD14</td>
<td>r</td>
<td>0.16</td>
</tr>
<tr>
<td></td>
<td>P</td>
<td>0.070</td>
</tr>
<tr>
<td>Fibrinogen</td>
<td>r</td>
<td></td>
</tr>
<tr>
<td></td>
<td>P</td>
<td></td>
</tr>
</tbody>
</table>

For HIV-infected women, prior to HAART initiation:
- Correlation coefficients (r) and significance levels (P) are provided for each biomarker.
- Significant correlations are highlighted.

For HIV-infected women, after HAART initiation:
- Similar correlation coefficients and significance levels are provided.
- Significant correlations are highlighted.

Note: HIV-infected women, prior to HAART initiation; HIV-infected women, after HAART initiation.
<table>
<thead>
<tr>
<th></th>
<th>HIV-uninfected women</th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>IL-10</td>
<td>TNF-a</td>
<td>D-dimer</td>
<td>MCP-1</td>
<td>sCD14</td>
<td>Fibrinogen</td>
<td>IL-2 sR</td>
<td></td>
</tr>
<tr>
<td>IL-6</td>
<td>r</td>
<td>0.16</td>
<td>0.23</td>
<td>0.23</td>
<td>-0.17</td>
<td>0.27</td>
<td>0.02</td>
<td>0.19</td>
</tr>
<tr>
<td></td>
<td>P</td>
<td>0.145</td>
<td>0.030</td>
<td>0.029</td>
<td>0.121</td>
<td>0.011</td>
<td>0.867</td>
<td>0.079</td>
</tr>
<tr>
<td>IL-10</td>
<td>r</td>
<td>0.65</td>
<td>0.18</td>
<td>0.18</td>
<td>0.28</td>
<td>-0.08</td>
<td>0.33</td>
<td></td>
</tr>
<tr>
<td></td>
<td>P</td>
<td>&lt;.0001</td>
<td>0.095</td>
<td>0.085</td>
<td>0.007</td>
<td>0.426</td>
<td>0.001</td>
<td></td>
</tr>
<tr>
<td>TNF-a</td>
<td>r</td>
<td>0.45</td>
<td>0.35</td>
<td>0.33</td>
<td>0.04</td>
<td>0.46</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>P</td>
<td>&lt;.0001</td>
<td>0.001</td>
<td>0.002</td>
<td>0.726</td>
<td>&lt;.0001</td>
<td></td>
<td></td>
</tr>
<tr>
<td>D-dimer</td>
<td>r</td>
<td>0.03</td>
<td>0.13</td>
<td>0.12</td>
<td>0.09</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>P</td>
<td>0.784</td>
<td>0.209</td>
<td>0.245</td>
<td>0.390</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>MCP-1</td>
<td>r</td>
<td>0.17</td>
<td>0.11</td>
<td>0.25</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>P</td>
<td>0.111</td>
<td>0.279</td>
<td>0.019</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>sCD14</td>
<td>r</td>
<td></td>
<td>0.06</td>
<td>0.37</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>P</td>
<td>0.557</td>
<td>0.37</td>
<td>&lt;.0001</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Fibrinogen</td>
<td>r</td>
<td></td>
<td>-0.01</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>P</td>
<td></td>
<td>0.910</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Correlations represent Pearson correlations of natural log-transformed biomarker levels.
Supplemental Table 2. Correlations of inflammation and coagulation biomarkers with current and nadir CD4+ T cell count, HIV RNA and clinical characteristics among HIV-infected women

<table>
<thead>
<tr>
<th></th>
<th>Age</th>
<th>Current CD4+ T Cell Count</th>
<th>Nadir CD4+ T Cell Count</th>
<th>HIV RNA</th>
<th>Smoking History (in years)</th>
<th>BMI</th>
<th>HCV Ab/RNA Status</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td>r</td>
<td>P</td>
<td>r</td>
<td>P</td>
<td>r</td>
<td>P</td>
</tr>
<tr>
<td>Prior to HAART initiation:</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>sCD14</td>
<td>0.18</td>
<td>0.04</td>
<td>-0.25</td>
<td>0.01</td>
<td>-0.29</td>
<td>&lt;0.01</td>
<td>0.41</td>
</tr>
<tr>
<td>TNF-alpha</td>
<td>0.04</td>
<td>0.65</td>
<td>-0.19</td>
<td>0.03</td>
<td>-0.22</td>
<td>0.01</td>
<td>0.24</td>
</tr>
<tr>
<td>IL-2 sR</td>
<td>0.02</td>
<td>0.78</td>
<td>-0.15</td>
<td>0.10</td>
<td>-0.28</td>
<td>&lt;0.01</td>
<td>0.42</td>
</tr>
<tr>
<td>IL-6</td>
<td>0.19</td>
<td>0.04</td>
<td>-0.18</td>
<td>0.05</td>
<td>-0.24</td>
<td>0.01</td>
<td>0.13</td>
</tr>
<tr>
<td>IL-10</td>
<td>-0.05</td>
<td>0.60</td>
<td>-0.22</td>
<td>0.01</td>
<td>-0.29</td>
<td>&lt;0.01</td>
<td>0.33</td>
</tr>
<tr>
<td>MCP-1</td>
<td>0.08</td>
<td>0.38</td>
<td>-0.14</td>
<td>0.12</td>
<td>-0.21</td>
<td>0.02</td>
<td>0.28</td>
</tr>
<tr>
<td>D-dimer</td>
<td>-0.02</td>
<td>0.79</td>
<td>-0.09</td>
<td>0.30</td>
<td>-0.14</td>
<td>0.11</td>
<td>0.18</td>
</tr>
<tr>
<td>Fibrinogen</td>
<td>0.18</td>
<td>0.05</td>
<td>0.03</td>
<td>0.72</td>
<td>-0.02</td>
<td>0.85</td>
<td>0.15</td>
</tr>
<tr>
<td>After HAART initiation</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>sCD14</td>
<td>0.10</td>
<td>0.25</td>
<td>-0.23</td>
<td>0.01</td>
<td>-0.23</td>
<td>0.01</td>
<td>0.14</td>
</tr>
<tr>
<td>TNF-alpha</td>
<td>0.06</td>
<td>0.50</td>
<td>-0.24</td>
<td>0.01</td>
<td>-0.29</td>
<td>&lt;0.01</td>
<td>0.28</td>
</tr>
<tr>
<td>IL-2 sR</td>
<td>0.04</td>
<td>0.66</td>
<td>-0.14</td>
<td>0.12</td>
<td>-0.26</td>
<td>&lt;0.01</td>
<td>0.31</td>
</tr>
<tr>
<td>IL-6</td>
<td>0.30</td>
<td>&lt;0.01</td>
<td>-0.18</td>
<td>0.05</td>
<td>-0.27</td>
<td>&lt;0.01</td>
<td>0.12</td>
</tr>
<tr>
<td>IL-10</td>
<td>-0.03</td>
<td>0.75</td>
<td>-0.21</td>
<td>0.02</td>
<td>-0.29</td>
<td>&lt;0.01</td>
<td>0.28</td>
</tr>
<tr>
<td>MCP-1</td>
<td>0.07</td>
<td>0.42</td>
<td>-0.08</td>
<td>0.39</td>
<td>-0.09</td>
<td>0.29</td>
<td>0.19</td>
</tr>
<tr>
<td>D-dimer</td>
<td>-0.08</td>
<td>0.40</td>
<td>-0.11</td>
<td>0.22</td>
<td>-0.10</td>
<td>0.28</td>
<td>0.22</td>
</tr>
<tr>
<td>Fibrinogen</td>
<td>0.23</td>
<td>0.01</td>
<td>0.01</td>
<td>0.92</td>
<td>0.01</td>
<td>0.93</td>
<td>0.12</td>
</tr>
</tbody>
</table>

r represents Pearson correlation coefficient
Biomarkers are natural log-transformed and HIV RNA is log10-transformed
**Supplemental Table 3. Correlation between HAART-associated change in CD4+ T cell count or HIV RNA and concomitant change in inflammation or hemostasis biomarkers**

<table>
<thead>
<tr>
<th>Biomarker change per 100 cell/mm³ increase in CD4+ T cell count</th>
<th>Biomarker change per log₁₀ decrease in HIV RNA</th>
<th>P</th>
<th>P</th>
</tr>
</thead>
<tbody>
<tr>
<td>Soluble CD14</td>
<td>-2%</td>
<td>&lt;.01</td>
<td>-2%</td>
</tr>
<tr>
<td>TNF-alpha</td>
<td>-8%</td>
<td>&lt;.0001</td>
<td>-11%</td>
</tr>
<tr>
<td>Soluble IL-2 receptor</td>
<td>-8%</td>
<td>&lt;.0001</td>
<td>-13%</td>
</tr>
<tr>
<td>IL-6</td>
<td>-5%</td>
<td>0.14</td>
<td>-2%</td>
</tr>
<tr>
<td>IL-10</td>
<td>-10%</td>
<td>&lt;.0001</td>
<td>-15%</td>
</tr>
<tr>
<td>MCP-1</td>
<td>-5%</td>
<td>&lt;.01</td>
<td>-6%</td>
</tr>
<tr>
<td>D-dimer</td>
<td>-3%</td>
<td>0.3</td>
<td>-3%</td>
</tr>
<tr>
<td>Fibrinogen</td>
<td>0</td>
<td>0.9</td>
<td>0</td>
</tr>
</tbody>
</table>

HAART, highly active antiretroviral therapy
Supplemental Table 4. Correlation of hepatitis C virus infection (HCV RNA+) with levels of circulating inflammation and coagulation biomarkers

<table>
<thead>
<tr>
<th></th>
<th>HIV-infected women</th>
<th>HIV-uninfected women</th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Prior to HAART</td>
<td>After HAART initiation</td>
<td></td>
</tr>
<tr>
<td>sCD14</td>
<td>0.27 &lt;0.01</td>
<td>0.13 0.16</td>
<td>0.45 &lt;0.01</td>
</tr>
<tr>
<td>TNF-alpha</td>
<td>0.14 0.13</td>
<td>0.20 0.03</td>
<td>0.32 &lt;0.01</td>
</tr>
<tr>
<td>IL-2sr</td>
<td>0.16 0.08</td>
<td>0.22 0.01</td>
<td>0.29 0.01</td>
</tr>
<tr>
<td>IL-6</td>
<td>0.34 &lt;0.01</td>
<td>0.31 &lt;0.01</td>
<td>0.25 0.02</td>
</tr>
<tr>
<td>IL-10</td>
<td>0.18 0.04</td>
<td>0.31 &lt;0.01</td>
<td>0.45 &lt;0.01</td>
</tr>
<tr>
<td>MCP-1</td>
<td>0.01 0.88</td>
<td>0.12 0.20</td>
<td>-0.02 0.84</td>
</tr>
<tr>
<td>D-dimer</td>
<td>-0.05 0.57</td>
<td>0.03 0.75</td>
<td>0.09 0.41</td>
</tr>
<tr>
<td>Fibrinogen</td>
<td>-0.07 0.43</td>
<td>-0.12 0.20</td>
<td>-0.25 0.02</td>
</tr>
</tbody>
</table>

$r$ represents Pearson correlation between presence or absence of hepatitis C virus infection (HCV RNA+) and natural log-transformed level of biomarker.

HAART, highly-active antiretroviral therapy
Supplemental Table 5. Levels of soluble CD14 (ng/mL) among HIV-infected women before and after initiation of highly-active antiretroviral therapy, and among HIV-uninfected women, in the presence or absence of hepatitis C infection

<table>
<thead>
<tr>
<th></th>
<th>HCV-infected women</th>
<th>HCV-uninfected women</th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>HIV-infected (N=27)</td>
<td>HIV-uninfected (N=32)</td>
<td>HIV-infected (N=100)</td>
<td>HIV-uninfected (N=95)</td>
</tr>
<tr>
<td><strong>Median sCD14, ng/mL</strong></td>
<td><strong>IQR</strong></td>
<td><strong>Median sCD14, ng/mL</strong></td>
<td><strong>IQR</strong></td>
<td><strong>P</strong></td>
</tr>
<tr>
<td><strong>1st visit</strong></td>
<td>2246</td>
<td>1623-2657</td>
<td>1872</td>
<td>1640-2169</td>
</tr>
<tr>
<td></td>
<td>1888</td>
<td>1612-2093</td>
<td>1509</td>
<td>1331-1781</td>
</tr>
<tr>
<td><strong>2nd visit</strong></td>
<td>2326</td>
<td>2120-2598</td>
<td>1923</td>
<td>1618-2125</td>
</tr>
<tr>
<td></td>
<td>1866</td>
<td>1636-2120</td>
<td>1564</td>
<td>1333-1824</td>
</tr>
<tr>
<td><strong>3rd visit</strong></td>
<td>2265</td>
<td>2048-2578</td>
<td>1966</td>
<td>1724-2293</td>
</tr>
<tr>
<td></td>
<td>1915</td>
<td>1586-2220</td>
<td>1566</td>
<td>1344-1877</td>
</tr>
<tr>
<td><strong>4th visit</strong></td>
<td>2115</td>
<td>1786-2461</td>
<td>2010</td>
<td>1729-2207</td>
</tr>
<tr>
<td></td>
<td>1891</td>
<td>1585-2142</td>
<td>1614</td>
<td>1371-1916</td>
</tr>
<tr>
<td><strong>5th visit</strong></td>
<td>1978</td>
<td>1604-2412</td>
<td>1990</td>
<td>1719-2268</td>
</tr>
<tr>
<td></td>
<td>1919</td>
<td>1655-2273</td>
<td>1566</td>
<td>1358-1834</td>
</tr>
<tr>
<td><strong>6th visit</strong></td>
<td>2126</td>
<td>1713-2420</td>
<td>2057</td>
<td>1735-2420</td>
</tr>
<tr>
<td></td>
<td>1956</td>
<td>1639-2180</td>
<td>1594</td>
<td>1414-1911</td>
</tr>
</tbody>
</table>

*P* values calculated using the Mann-Whitney test. HCV infection status was defined as presence or absence of circulating HCV RNA.

HCV, hepatitis C virus; IQR, interquartile range
Supplemental Figure 1. Levels of soluble CD14 (ng/mL) among HIV-infected women before and after initiation of highly-active antiretroviral therapy, and among HIV-uninfected women, in the presence or absence of hepatitis C infection.

Blue diamonds indicate median values among HIV-infected women at six semi-annual study visits. Red x’s indicate median values among HIV-uninfected women. Green arrow indicates time of HAART initiation. HCV infection status was defined as presence or absence of circulating HCV RNA.

HCV, hepatitis C virus; HAART, highly-active antiretroviral therapy.